FFO
ADMA icon

Fortitude Family Office’s ADMA Biologics ADMA Stock Holding History

Fortitude Family Office’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-49
Closed -$441 – 2272
2026
Q1 		$441 Buy
49
+31
+172% +$489 ﹤0.01% 1772
2025
Q4 		$328 Hold
18
– – ﹤0.01% 1809
2025
Q3 		$264 Sell
18
-12
-40% -$206 ﹤0.01% 1913
2025
Q2 		$546 Buy
+30
New +$612 ﹤0.01% 1758

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Fortitude Family Office's ADMA Position: Q2 2026 in Review

Fortitude Family Office sold out of ADMA Biologics (ADMA) in Q2 2026, closing a stake of 49 shares — an estimated $441 sold.

Fortitude Family Office first reported a position in ADMA in Q2 2025 and held it in 4 quarters. The position peaked at $546 in Q2 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Fortitude Family Office reported no remaining ADMA Biologics position as of Q2 2026 after selling out during the quarter.
  • Fortitude Family Office sold 49 ADMA Biologics shares in Q2 2026, an estimated $441.
  • Fortitude Family Office first reported a position in ADMA Biologics in Q2 2025 and held it in 4 quarters.
  • Fortitude Family Office's ADMA Biologics position peaked at $546 in Q2 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.